{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:16:21Z","timestamp":1790205381613,"version":"4.1.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Deficiency of adenosine deaminase 2 (DADA2) is an inherited autosomal recessive disease characterized by autoinflammation (recurrent fever), vasculopathy (livedo racemosa, polyarteritis nodosa, lacunar ischemic strokes, and intracranial hemorrhages, end organ vasculitis), immunodeficiency, lymphoproliferation, immune cytopenias, and bone marrow failure. Allogeneic hematopoietic cell transplantation (HCT) is curative for DADA2 as it reverses the hematological, immune and vascular phenotype of DADA2. The primary goal of HCT in DADA2, like in other non-malignant diseases, is engraftment with the establishment of normal hematopoiesis and normal immune function. Strategies in selecting a preparative regimen should take into consideration the specific vulnerabilities to endothelial dysfunction and liver toxicity in DADA2 patients. Overcoming an increased risk of graft rejection while minimizing organ toxicity, graft-versus-host disease, and infections can be particularly challenging in DADA2 patients. This review will discuss approaches to HCT in DADA2 patients including disease-specific considerations, barriers to successful engraftment, post-HCT complications, and clinical outcomes of published patients with DADA2 who have undergone HCT to date.<\/jats:p>","DOI":"10.3389\/fimmu.2022.932385","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T06:25:13Z","timestamp":1657175113000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Allogeneic Hematopoietic Cell Transplantation for Patients With Deficiency of Adenosine Deaminase 2 (DADA2): Approaches, Obstacles and Special Considerations"],"prefix":"10.3389","volume":"13","author":[{"given":"Hasan","family":"Hashem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimana","family":"Dimitrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Meyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307361","article-title":"Early-Onset Stroke and Vasculopathy Associated With Mutations in ADA2","volume":"370","author":"Zhou","year":"2014","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307362","article-title":"Mutant Adenosine Deaminase 2 in a Polyarteritis Nodosa Vasculopathy","volume":"370","author":"Navon Elkan","year":"2014","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11926-017-0699-8","article-title":"Deficiency of Adenosine Deaminase 2 (DADA2), an Inherited Cause of Polyarteritis Nodosa and a Mimic of Other Systemic Rheumatologic Disorders","volume":"19","author":"Hashem","year":"2017","journal-title":"Curr Rheumatol Rep Curr Rheumatol Reports"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00817-3","article-title":"Deficiency of Adenosine Deaminase 2 (DADA2): Hidden Variants, Reduced Penetrance, and Unusual Inheritance","volume":"40","author":"Schnappauf","year":"2020","journal-title":"J Clin Immunol J Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12969-016-0111-7","article-title":"Monogenic Polyarteritis: The Lesson of ADA2 Deficiency","volume":"14","author":"Caorsi","year":"2016","journal-title":"Pediatr Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181384","article-title":"A Monogenic Disease With a Variety of Phenotypes: Deficiency of Adenosine Deaminase 2","volume":"47","author":"\u00d6zen","year":"2020","journal-title":"J Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000805","article-title":"Refractory Pure Red Cell Aplasia Manifesting as Deficiency of Adenosine Deaminase 2","volume":"39","author":"Hashem","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2016.06.058","article-title":"Extending the Clinical Phenotype of Adenosine Deaminase 2 Deficiency","volume":"177","author":"Ben-Ami","year":"2016","journal-title":"J Pediatr"},{"key":"B9","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1056\/NEJMc1405506","article-title":"Mutant ADA2 in Vasculopathies","volume":"371","author":"Van Eyck","year":"2014","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-018-0525-8","article-title":"Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment","volume":"38","author":"Meyts","year":"2018","journal-title":"J Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-017-3740-3","article-title":"Clinical, Imaging and Genotypical Features of Three Deceased and Five Surviving Cases With ADA2 Deficiency","volume":"1","author":"Sahin","year":"2017","journal-title":"Rheumatol Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/art.41500","article-title":"Deficiency of Adenosine Deaminase 2 (DADA2) in Adults and Children: Experience From India","volume":"73","author":"Sharma","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150024","article-title":"A Case Series of Adenosine Deaminase 2-Deficient Patients Emphasizing Treatment and Genotype-Phenotype Correlations in Rheumatology and Related Fields","volume":"42","author":"Batu","year":"2015","journal-title":"J Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa837","article-title":"Anti-Tumour Necrosis Factor Treatment for the Prevention of Ischaemic Events in Patients With Deficiency of Adenosine Deaminase 2 (DADA2)","volume":"60","author":"Cooray","year":"2021","journal-title":"Rheumatol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1801927","article-title":"Treatment Strategies for Deficiency of Adenosine Deaminase 2","volume":"380","author":"Ombrello","year":"2020","journal-title":"HHS Public Access"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.jaci.2019.12.908","article-title":"Genotype and Functional Correlates of Disease Phenotype in Deficiency of Adenosine Deaminase 2 (DADA2)","volume":"145","author":"Lee","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-798660","article-title":"Hematopoietic Stem Cell Transplantation Rescues the Hematological, Immunological, and Vascular Phenotype in DADA2","volume":"130","author":"Hashem","year":"2017","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01098-0","article-title":"Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients","volume":"41","author":"Hashem","year":"2021","journal-title":"J Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1546-0096-12-44","article-title":"Mutations in CECR1 Associated With a Neutrophil Signature in Peripheral Blood","volume":"12","author":"Belot","year":"2014","journal-title":"Pediatr Rheumatol Online J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1182\/blood.2018892752","article-title":"Deficiency of Adenosine Deaminase 2 Triggers Adenosine-Mediated NETosis and TNF Production in Patients With DADA2","volume":"134","author":"Carmona-Rivera","year":"2019","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrrheum.2014.158","article-title":"New Players Driving Inflammation in Monogenic Autoinflammatory Diseases","volume":"11","author":"Martinon","year":"2014","journal-title":"Nat Rev Rheumatol Nat Publ Group"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1109764","article-title":"Human Adenosine Deaminase 2 Induces Differentiation of Monocytes Into Macrophages and Stimulates Proliferation of T Helper Cells and Macrophages","volume":"88","author":"Zavialov","year":"2010","journal-title":"J Leukoc Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2357-0","article-title":"Human Adenosine Deaminases ADA1 and ADA2 Bind to Different Subsets of Immune Cells","volume":"74","author":"Kaljas","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba3688","article-title":"Cellular Sensing of Extracellular Purine Nucleosides Triggers an Innate IFN-\u03b2 Response","volume":"6","author":"Dhanwani","year":"2020","journal-title":"Sci Adv"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.01.018","article-title":"Detailed Analysis of Japanese Patients With Adenosine Deaminase 2 Deficiency Reveals Characteristic Elevation of Type II Interferon Signature and STAT1 Hyperactivation","volume":"148","author":"Nihira","year":"2021","journal-title":"J Allergy Clin Immunol Elsevier Inc.;"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180045","article-title":"Variable Clinical Phenotypes and Relation of Interferon Signature With Disease Activity in ADA2 Deficiency","volume":"46","author":"Insalaco","year":"2019","journal-title":"J Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2021.1881156","article-title":"Diagnosis of Deficiency of Adenosine Deaminase Type 2 in Adulthood","volume":"50","author":"Betrains","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-022-00918-8","article-title":"Mechanisms of Vascular Inflammation in Deficiency of Adenosine Deaminase 2 (DADA2)","volume":"44","author":"Lee","year":"2022","journal-title":"Semin Immunopathol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11926-020-00944-1","article-title":"The Many Faces of a Monogenic Autoinflammatory Disease: Adenosine Deaminase 2 Deficiency","volume":"22","author":"Kendall","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.18176\/jiaci.0748","article-title":"Treatment and Outcome in Deficiency of Adenosine Deaminase 2: A Literature Review","volume":"32","author":"Zhang","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.811473","article-title":"The Spectrum of the Deficiency of Adenosine Deaminase 2: An Observational Analysis of a 60 Patient Cohort","volume":"12","author":"Barron","year":"2022","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01141-0","article-title":"Intrinsic Defects in B Cell Development and Differentiation, T Cell Exhaustion and Altered Unconventional T Cell Generation Characterize Human Adenosine Deaminase Type 2 Deficiency","volume":"41","author":"Yap","year":"2021","journal-title":"J Clin Immunol Springer US"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0245-x","article-title":"Deficiency of Adenosine Deaminase 2 Causes Antibody Deficiency","volume":"36","author":"Schepp","year":"2016","journal-title":"J Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/art.40147","article-title":"Screening of 181 Patients With Antibody Deficiency for Deficiency of Adenosine Deaminase 2 Sheds New Light on the Disease in Adulthood","volume":"69","author":"Schepp","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00812-8","article-title":"Late-Onset EBV Susceptibility and Refractory Pure Red Cell Aplasia Revealing Dada2","volume":"40","author":"Le Voyer","year":"2020","journal-title":"J Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00940-1","article-title":"Uncontrolled Epstein-Barr Virus as an Atypical Presentation of Deficiency in ADA2 (Dada2)","volume":"41","author":"Brooks","year":"2021","journal-title":"J Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202048549","article-title":"Dysregulation in B-Cell Responses and T Follicular Helper Cell Function in ADA2 Deficiency Patients","volume":"57","author":"Schena","year":"2020","journal-title":"Eur J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.173","article-title":"Successful Reduced Intensity Hematopoietic Cell Transplant in a Patient With Deficiency of Adenosine Deaminase 2","volume":"52","author":"Hashem","year":"2017","journal-title":"Bone Marrow Transpl"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.10.010","article-title":"Hematopoietic Stem Cell Transplantation Rescues the Immunologic Phenotype and Prevents Vasculopathy in Patients With Adenosine Deaminase 2 Deficiency","volume":"135","author":"Van Eyck","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-0590-7","article-title":"Childhood Hodgkin Lymphoma: Think Dada2","volume":"39","author":"Alabbas","year":"2019","journal-title":"J Clin Immunol J Clin Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02767","article-title":"ALPS-Like Phenotype Caused by ADA2 Deficiency Rescued by Allogeneic Hematopoietic Stem Cell Transplantation","volume":"9","author":"Barzaghi","year":"2019","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.jaci.2018.01.012","article-title":"ADA2 Deficiency: Clonal Lymphoproliferation in a Subset of Patients","volume":"141","author":"Trotta","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00251-018-01101-w","article-title":"A Chinese DADA2 Patient: Report of Two Novel Mutations and Successful HSCT","volume":"71","author":"Liu","year":"2019","journal-title":"Immunogenetics"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/art.40913","article-title":"Identification of Novel Adenosine Deaminase 2 Gene Variants and Varied Clinical Phenotype in Pediatric Vasculitis","volume":"71","author":"Gibson","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-169342","article-title":"Sirolimus is Associated With Veno-Occlusive Disease of the Liver After Myeloablative Allogeneic Stem Cell Transplantation","volume":"112","author":"Cutler","year":"2008","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0705-z","article-title":"Prophylactic, Preemptive, and Curative Treatment for Sinusoidal Obstruction Syndrome\/Veno-Occlusive Disease in Adult Patients: A Position Statement From an International Expert Group","volume":"55","author":"Mohty","year":"2020","journal-title":"Bone Marrow Transpl Springer US"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01378-8","article-title":"EBMT\/ESID Inborn Errors Working Party Guidelines for Hematopoietic Stem Cell Transplantation for Inborn Errors of Immunity","volume":"56","author":"Lankester","year":"2021","journal-title":"Bone Marrow Transpl Springer US"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210802","article-title":"ADA2 Deficiency ( DADA2 ) as an Unrecognised Cause of Early Onset Polyarteritis Nodosa and Stroke : A Multicentre National Study","volume":"76","author":"Caorsi","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.04.023","article-title":"Deficiency of Adenosine Deaminase 2: Is it an Elephant After All","volume":"145","author":"Schnappauf","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10875-022-01271-z","article-title":"Common Variable Immunodeficiency in a Carrier of the ADA2 R169Q Variant: Coincidence or Causality","author":"Moi","year":"2022","journal-title":"J Clin Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-017-0449-8","article-title":"Hematopoietic Stem Cell Transplantation in ADA2 Deficiency: Early Restoration of ADA2 Enzyme Activity and Disease Relapse Upon Drop of Donor Chimerism","volume":"37","author":"Bucciol","year":"2017","journal-title":"J Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.932385\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T14:30:10Z","timestamp":1657895410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.932385\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2022.932385"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.932385","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"article-number":"932385"}}